Next Article in Journal
Polysaccharide-Rich Fraction of Noni Fruit (Morinda citrifolia L.) as Doxorubicin Co-Chemotherapy: Evaluation of Catalase, Macrophages, and TCD8+ Lymphocytes
Previous Article in Journal
Cost-Effective Isolation of a Process Impurity of Pregabalin
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2015, 83(3), 465-478; doi:10.3797/scipharm.1502-04

A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil

1
Chemical Research and Development, Aurobindo Pharma Pvt Ltd, Survey No. 71& 72, Indrakaran Village, Sangareddy Mandal, Medak District, Telangana-502329, India
2
Department of Chemistry, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur District, Andhra Pradesh-522510, India
*
Authors to whom correspondence should be addressed.
Received: 15 February 2015 / Accepted: 31 March 2015 / Published: 31 March 2015
Download PDF [157 KB, uploaded 8 September 2016]

Abstract

Drug product purity and potency are of most significance in the regulatory market as we notice many recalled batches worldwide, particularly in the US and Japan. Olmesartan Medoxomil is an anti-hypertensive drug. The present invention relates to a process for the preparation of Olmesartan Medoxomil with 99.9% purity in an overall 62% yield. The synthesis includes three isolations and one purification with easy plant operations. This process describes the formation and control of each individual impurity in all stages. This process for Olmesartan Medoxomil and its intermediates is competent for industrial production in very short reaction time intervals with an appreciable yield and high purity.
Keywords: Olmesartan medoxomil; Process Development; Impurities; Synthesis; Anti-hypertensive Drug Olmesartan medoxomil; Process Development; Impurities; Synthesis; Anti-hypertensive Drug
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

HANUMANTHA RAO, B.; SUBRAMANYESWARA RAO, I.V.; RAVI KANTH, V.; PRASADA RAO, K.V.V.; BALAMURALI KRISHNA, K.; SYAMA SUNDAR, B. A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil. Sci. Pharm. 2015, 83, 465-478.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top